Status:
COMPLETED
Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)
Lead Sponsor:
Susan J. Hayflick
Collaborating Sponsors:
Oregon Health and Science University
Oregon Clinical and Translational Research Institute
Conditions:
Pantothenate Kinase-associated Neurodegeneration (PKAN)
Eligibility:
All Genders
7-75 years
Brief Summary
The purpose of this study is to learn whether blood flow in the brain is normal in people with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data suggest a region ...
Eligibility Criteria
Inclusion
- diagnosis of PKAN confirmed by MRI and gene testing
- able to undergo MRI for approximately 1 hour without sedation
Exclusion
- deep brain stimulators or other conditions that warrant avoidance of a strong magnetic field
- previous reaction to gadolinium (Gd) contrast agent
- acute or chronic kidney dysfunction
- pregnant and/or nursing at time of study
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01838018
Start Date
April 1 2013
End Date
January 1 2018
Last Update
May 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239